Literature DB >> 27578767

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Theresa M Carbonaro1, Matthew P Bradstreet1, Frederick S Barrett1, Katherine A MacLean1, Robert Jesse1,2, Matthew W Johnson1, Roland R Griffiths3,4.   

Abstract

Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst "bad trip") after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging experiences of his/her lifetime. Eleven percent put self or others at risk of physical harm; factors increasing the likelihood of risk included estimated dose, duration and difficulty of the experience, and absence of physical comfort and social support. Of the respondents, 2.6% behaved in a physically aggressive or violent manner and 2.7% received medical help. Of those whose experience occurred >1 year before, 7.6% sought treatment for enduring psychological symptoms. Three cases appeared associated with onset of enduring psychotic symptoms and three cases with attempted suicide. Multiple regression analysis showed degree of difficulty was positively associated, and duration was negatively associated, with enduring increases in well-being. Difficulty of experience was positively associated with dose. Despite difficulties, 84% endorsed benefiting from the experience. The incidence of risky behavior or enduring psychological distress is extremely low when psilocybin is given in laboratory studies to screened, prepared, and supported participants.
© The Author(s) 2016.

Entities:  

Keywords:  Psilocybin; adverse effects; bad trip; hallucinogen; human; psychedelic; survey

Mesh:

Substances:

Year:  2016        PMID: 27578767      PMCID: PMC5551678          DOI: 10.1177/0269881116662634

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  27 in total

1.  Drug harms in the UK: a multicriteria decision analysis.

Authors:  David J Nutt; Leslie A King; Lawrence D Phillips
Journal:  Lancet       Date:  2010-10-29       Impact factor: 79.321

2.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

Review 3.  Psilocybin--summary of knowledge and new perspectives.

Authors:  Filip Tylš; Tomáš Páleníček; Jiří Horáček
Journal:  Eur Neuropsychopharmacol       Date:  2013-12-17       Impact factor: 4.600

4.  Psilocybin, psychological distress, and suicidality.

Authors:  Peter S Hendricks; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-09       Impact factor: 4.153

5.  Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer.

Authors:  J Bigwood; M W Beug
Journal:  J Ethnopharmacol       Date:  1982-05       Impact factor: 4.360

6.  Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

Authors:  Erich Studerus; Michael Kometer; Felix Hasler; Franz X Vollenweider
Journal:  J Psychopharmacol       Date:  2010-09-20       Impact factor: 4.153

Review 7.  Hallucinogen persisting perception disorder: what do we know after 50 years?

Authors:  John H Halpern; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2003-03-01       Impact factor: 4.492

8.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

9.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

10.  Psychometric evaluation of the altered states of consciousness rating scale (OAV).

Authors:  Erich Studerus; Alex Gamma; Franz X Vollenweider
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

View more
  71 in total

1.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

2.  High dose psilocybin is associated with positive subjective effects in healthy volunteers.

Authors:  Christopher R Nicholas; Kelsey M Henriquez; Michele C Gassman; Karen M Cooper; Daniel Muller; Scott Hetzel; Randall T Brown; Nicholas V Cozzi; Chantelle Thomas; Paul R Hutson
Journal:  J Psychopharmacol       Date:  2018-06-27       Impact factor: 4.153

3.  Neuroticism is associated with challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  Pers Individ Dif       Date:  2017-06-07

4.  Replication and extension of a model predicting response to psilocybin.

Authors:  Suzanne L Russ; R L Carhart-Harris; G Maruyama; M S Elliott
Journal:  Psychopharmacology (Berl)       Date:  2019-06-15       Impact factor: 4.530

5.  Two Models of Legalization of Psychedelic Substances: Reasons for Concern.

Authors:  William R Smith; Paul S Appelbaum
Journal:  JAMA       Date:  2021-08-24       Impact factor: 56.272

6.  Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes.

Authors:  Gabrielle Agin-Liebes; Trevor F Haas; Rafael Lancelotta; Malin V Uthaug; Johannes G Ramaekers; Alan K Davis
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-23

Review 7.  Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.

Authors:  Jacob S Aday; Alan K Davis; Cayla M Mitzkovitz; Emily K Bloesch; Christopher C Davoli
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-05

Review 8.  Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.

Authors:  Jake E Payne; Richard Chambers; Paul Liknaitzky
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-16

Review 9.  On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.

Authors:  Richard J Zeifman; Nikhita Singhal; Leah Breslow; Cory R Weissman
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-11

10.  Relational Processes in Ayahuasca Groups of Palestinians and Israelis.

Authors:  Leor Roseman; Yiftach Ron; Antwan Saca; Natalie Ginsberg; Lisa Luan; Nadeem Karkabi; Rick Doblin; Robin Carhart-Harris
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.